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Errata
Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EAM, Howard BV, Kirkman MS, Kosiborod M, Reaven P,
Sherwin RS: Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD,
ADVANCE, and VA Diabetes trials: a position statement of the American Diabetes Association and a scientiﬁc statement of
the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 32:187–192, 2009
The following statement should appear in the ACKNOWLEDGMENTS concerning the potential dualities of interest of Richard Bergenstal:
R.B. participates in clinical research or has served on a scientiﬁc advisory board for Amylin, Merck, Pﬁzer, ResMed, Valeritas, Eli
Lilly, Novo Nordisk, sanoﬁ-aventis, MannKind, Intuity, Roche, LifeScan, Abbott, Bayer, and Medtronic. R.B. receives no personal
compensation for these activities; all contracts are through the nonproﬁt Park Nicollet Institute. R.B. holds stock in Merck through
a family inheritance and is an ofﬁcer within the American Diabetes Association.
The online version reﬂects these changes.
American Diabetes Association: Summary of revisions for the 2009 Clinical Practice Recommendations. Diabetes Care 32
(Suppl. 1):S3–S5, 2009
In the print version of the article listed above, the term “CHF” is deﬁned as “coronary heart failure.” The term should be deﬁned as
“congestive heart failure” instead. The online version reﬂects these changes.
AmericanDiabetesAssociation:Executivesummary:standardsofmedicalcareindiabetes—2009.DiabetesCare32(Suppl.
1):S6–S12, 2009
In the print version of the article listed above, the term “CHF” is deﬁned as “coronary heart failure.” The term should be deﬁned as
“congestive heart failure” instead. In addition, in the section entitled “Prevention/Delay of Type 2 Diabetes,” two additional bullets
with accompanying text should appear as follows:
● In addition to lifestyle counseling, metformin may be considered in those who are at very high risk for developing diabetes
(combined IFG and IGT plus other risk factors such as A1C 6%, hypertension, low HDL cholesterol, elevated triglycerides, or
family history of diabetes in a ﬁrst-degree relative) and who are obese and under 60 years of age. (E).
● Monitoring for the development of diabetes in those with pre-diabetes should be performed every year. (E).
The online version reﬂects these changes.
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